Pre-clinical assessment of poly-arginine peptide R18D as a therapeutic to reduce central nervous system injury following neurotrauma. Meloni/Knuckey/Hodgetts/Cross. 2017: $99,650. Neurotrauma Research Program of WA.

Pre-clinical assessment of the neuroprotective efficacy of arginine-rich peptides in neurotrauma injury models. Meloni/Knuckey/Hodgetts/Cross. 2016: $113,636. Neurotrauma Research Program of WA.

Dr Jane Cross, A/Prof Bruno Meloni, Clp Neville Knuckey, Dr David Blacker 2015, ‘Pre-clinical Assessment of Poly-arginine Peptides as a Treatment to Reduce Brain Damage Following Stroke’, National Stroke Foundation.

A/Prof Bruno Meloni, Clp Neville Knuckey, Ms Li Chiu, Dr Jane Cross, Mr Vince Clark 2015-16, ‘Pre-clinical assessment of arginine-rich peptides as a treatment to reduce brain damage following traumatic brain injury’, Brain Foundation.


Dr Jane Cross is a Research Officer in the Stroke Research group at the Perron Institute.
Dr Cross Graduated with a Bachelor of Science from the University of Canterbury, Christchurch, New Zealand, in 2001 and in 2011 completed her PhD through the School of Medicine and Pharmacology at The University of Western Australia.